Laser ablation of 91%+ tumor volume extends glioblastoma survival to 2.1 years in multicenter cohort

The Journal of Clinical Oncology analysis pooled prospective data from 25 U.S. centers using the NeuroBlate system. Real-time MRI thermometry guided robotic probe placement through a 3-4 mm burr hole, delivering thermal doses that produced immediate coagulative necrosis. Extent of ablation emerged as the dominant modifiable predictor; patients below the 91% threshold showed no survival gain over historical controls receiving biopsy plus chemoradiation alone. For recurrent brain metastases previously irradiated, LITT conferred an additional 4.3-month median survival advantage when ablation exceeded 85%.

Standard GBM management relies on maximal safe resection followed by temozolomide and radiation, yet eloquent or deep-seated lesions preclude gross-total removal in roughly 30% of cases. The current study supplies the first large-scale evidence that upfront LITT can substitute for open craniotomy when ablation volume is optimized, a finding absent from earlier single-center series and FDA clearance documents focused on recurrent disease. Quality-of-life metrics were not reported, leaving open whether reduced surgical morbidity offsets any decrement in cytoreduction.

Next steps require a randomized trial comparing LITT plus standard adjuvant therapy against open resection in operable patients, with overall survival and neurocognitive preservation as co-primary endpoints. Such a study would also need to stratify by MGMT methylation and IDH status to isolate treatment effects from molecular prognosis.